Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
M Polack, M A Smit, G W van Pelt, A G H Roodvoets, E Meershoek-Klein Kranenbarg, H Putter, H Gelderblom, A S L P Crobach, V Terpstra, G Petrushevska, G Gašljević, S Kjær-Frifeldt, E M V de Cuba, N W J Bulkmans, G R Vink, R Al Dieri, R A E M Tollenaar, J H J M van Krieken, W E Mesker
BACKGROUND: The TNM (tumor-node-metastasis) Evaluation Committee of Union for International Cancer Control (UICC) and College of American Pathologists (CAP) recommended to prospectively validate the cost-effective and robust tumor-stroma ratio (TSR) as an independent prognostic parameter, since high intratumor stromal percentages have previously predicted poor patient-related outcomes. PATIENTS AND METHODS: The 'Uniform Noting for International application of Tumor-stroma ratio as Easy Diagnostic tool' (UNITED) study enrolled patients in 27 participating centers in 12 countries worldwide...
April 12, 2024: ESMO Open
#2
JOURNAL ARTICLE
Seiichi Hirota, Ukihide Tateishi, Yuji Nakamoto, Hidetaka Yamamoto, Shinji Sakurai, Hirotoshi Kikuchi, Tatsuo Kanda, Yukinori Kurokawa, Haruhiko Cho, Toshirou Nishida, Akira Sawaki, Masato Ozaka, Yoshito Komatsu, Yoichi Naito, Yoshitaka Honma, Fumiaki Takahashi, Hironobu Hashimoto, Midori Udo, Minako Araki, Sumito Nishidate
The Japan Society of Clinical Oncology Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) have been published in accordance with the Minds Manual for Guideline Development 2014 and 2017. A specialized team independent of the working group for the revision performed a systematic review. Since GIST is a rare type of tumor, clinical evidence is not sufficient to answer several clinical and background questions. Thus, in these guidelines, we considered that consensus among the experts who manage GIST, the balance between benefits and harms, patients' wishes, medical economic perspective, etc...
April 13, 2024: International Journal of Clinical Oncology
#3
REVIEW
Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annalisa Trama, Sebastian Asaftei, Giuseppe Badalamenti, Rossella Bertulli, Alexia Francesca Bertuzzi, Roberto Biagini, Angela Bonadonna, Antonella Brunello, Dario Callegaro, Ferdinando Cananzi, Marco Cianchetti, Paola Collini, Danila Comandini, Annalisa Curcio, Lorenzo D'Ambrosio, Tommaso De Pas, Angelo Paolo Dei Tos, Virginia Ferraresi, Andrea Ferrari, Alessandro Franchi, Anna Maria Frezza, Elena Fumagalli, Matteo Ghilli, Daniela Greto, Giovanni Grignani, Michele Guida, Toni Ibrahim, Marco Krengli, Roberto Luksch, Andrea Marrari, Marinella Mastore, Alessandra Merlini, Giuseppe Maria Milano, Piera Navarria, Maria Abbondanza Pantaleo, Antonina Parafioriti, Ilaria Pellegrini, Elisabetta Pennacchioli, Marco Rastrelli, Elisabetta Setola, Salvatore Tafuto, Salvatore Turano, Sergio Valeri, Bruno Vincenzi, Viviana Vitolo, Andrei Ivanescu, Fiammetta Paloschi, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas. While the current European Society of Medical Oncology (ESMO) clinical practice guidelines for sarcoma treatment are applicable to AS, its unique aggressiveness and diverse tumor presentations necessitate dedicated and detailed clinical recommendations, which are currently lacking. Notably, considerations regarding surgical extent, radiation therapy (RT), and neoadjuvant/adjuvant chemotherapy vary significantly in localized disease, depending on each different site of onset...
March 30, 2024: Cancer Treatment Reviews
#4
REVIEW
Samantha K F Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C Y Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J Gralla, Terry L Ng, Katarzyna J Jerzak
Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking...
April 10, 2024: Supportive Care in Cancer
#5
JOURNAL ARTICLE
Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera
PURPOSE: Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile. METHODS: A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines...
April 5, 2024: Clinical & Translational Oncology
#6
JOURNAL ARTICLE
Emma L Boys, Bo Gao, Peter Grimison, Sarah Sutherland, Karen L MacKenzie, Roger R Reddel, Jia Liu
BACKGROUND: Carcinoma of unknown primary (CUP) remains an important tumor entity and a disproportionate cause of cancer mortality. Little is known about the contemporary clinical characteristics, treatment patterns, and outcomes of CUP patients based on updated international classification guidelines. We evaluated a contemporary CUP cohort to provide insight into current clinical practice and the impact of tissue of origin assignment, site-specific and empirical therapy in a real-world setting...
March 2024: Cancer Medicine
#7
JOURNAL ARTICLE
Teresa Kraus, Natalia Shengelia-de Lange, Holger Einspieler, Marcus Hacker, Alexander Haug, Elisabeth Kretschmer-Chott, Georgios Karanikas
BACKGROUND: The most important part of the follow-up of differentiated thyroid carcinoma (DTC) is the measurement of serum thyroglobulin (Tg). An increase of Tg levels indicates likely tumor recurrence. According to the guidelines of the European Society of Medical Oncology (ESMO) the follow-up should consist of serum Tg assays and a neck ultrasound, while the American Thyroid Association (ATA) recommends serum Tg assays, neck ultrasounds, and a diagnostic radioiodine Whole Body Scan (WBS) if non-stimulated Tg is greater than 10ng/mL or if Tg is rising...
March 1, 2024: Endocrine Connections
#8
T Powles, J Bellmunt, E Comperat, M De Santis, R Huddart, Y Loriot, A Necchi, B P Valderrama, A Ravaud, S F Shariat, B Szabados, M S van der Heijden, S Gillessen
No abstract text is available yet for this article.
March 13, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#9
JOURNAL ARTICLE
Yung-Taek Ouh, Yoonji Oh, Jinwon Joo, Joo Hyun Woo, Hye Jin Han, Hyun Woong Cho, Jae Kwan Lee, Yikyeong Chun, Myoung-Nam Lim, Jin Hwa Hong
This study aimed to evaluate the efficacy of the 2020 European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology (ESGO/ESTRO/ESP) guidelines for endometrial cancer (EC). Additionally, a novel risk category incorporating clinicopathological and molecular factors was introduced. The predictive value of this new category for recurrence and survival in Korean patients with EC was assessed, and comparisons were made with the 2013 and 2016 European Society of Medical Oncology (ESMO) risk classifications...
February 27, 2024: Cancers
#10
K Shitara, T Fleitas, H Kawakami, G Curigliano, Y Narita, F Wang, S O Wardhani, M Basade, S Y Rha, W I Wan Zamaniah, D L Sacdalan, M Ng, K H Yeh, P Sunpaweravong, E Sirachainan, M-H Chen, W P Yong, J L Peneyra, M N Ibtisam, K-W Lee, V Krishna, R R Pribadi, J Li, A Lui, T Yoshino, E Baba, I Nakayama, G Pentheroudakis, H Shoji, A Cervantes, C Ishioka, E Smyth
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer (GC), published in late 2022 and the updated ESMO Gastric Cancer Living Guideline published in July 2023, were adapted in August 2023, according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with GC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with GC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), coordinated by ESMO and the Japanese Society of Medical Oncology (JSMO)...
February 2024: ESMO Open
#11
J Herrstedt, R Clark-Snow, C H Ruhlmann, A Molassiotis, I Olver, B L Rapoport, M Aapro, K Dennis, P J Hesketh, R M Navari, L Schwartzberg, M L Affronti, M A Garcia-Del-Barrio, A Chan, L Celio, R Chow, M Fleury, R J Gralla, R Giusti, F Jahn, H Iihara, E Maranzano, V Radhakrishnan, M Saito, P Sayegh, S Bosnjak, L Zhang, J Lee, V Ostwal, T Smit, A Zilic, K Jordan, F Scotté
• Nausea and vomiting are considered amongst the most troublesome adverse events for patients receiving antineoplastics. • The guideline covers emetic risk classification, prevention and management of treatment-induced nausea and vomiting. • The Consensus Committee consisted of 34 multidisciplinary, health care professionals and three patient advocates. • Recommendations are based on evidence-based data (level of evidence) and the authors’ collective expert opinion (grade)...
February 2024: ESMO Open
#12
JOURNAL ARTICLE
Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu
BACKGROUND: The management of chemotherapy induced anemia (CIA) remains challenging. The potential risk and benefits in providing patient-centered care need to be balanced; the disease is multifactorial; and the major treatments including red blood cell (RBC) transfusions, erythropoiesis-stimulating agents (ESAs) and intravenous injection (i.v.)iron supplementation have a unique set of strengths and limitations. Also, most previous survey based on the patient data could not reveal the process of evaluation and decision-making for CIA treatment from a physician's perspective...
February 2024: Chinese Clinical Oncology
#13
JOURNAL ARTICLE
Kanji Nakagawa, Koji Takano, Kazumi Nishino, Shuichi Ohe, Takahiro Nakayama, Hideyuki Arita
PURPOSE: The number of leptomeningeal metastasis (LM) patients has increased in recent years, as the cancer survival rates increased. An optimal prediction of prognosis is essential for selecting an appropriate treatment. The European Association of Neuro-Oncology-European Society for Medical Oncology (EANO-ESMO) guidelines for LM proposed a classification based on the cerebrospinal fluid cytological findings and contrast-enhanced magnetic resonance imaging (MRI) pattern. However, few studies have validated the utility of this classification...
March 2, 2024: Journal of Neuro-oncology
#14
REVIEW
Kawthar Safi, Jan Sobieraj, Michał Błaszkiewicz, Joanna Żyła, Bartłomiej Salata, Tomasz Dzierżanowski
In light of the current International Association for the Study of Pain (IASP) clinical practice guidelines (CPGs) and the European Society for Medical Oncology (ESMO) guidelines, the topic of cannabinoids in relation to pain remains controversial, with insufficient research presently available. Cannabinoids are an attractive pain management option due to their synergistic effects when administered with opioids, thereby also limiting the extent of respiratory depression. On their own, however, cannabinoids have been shown to have the potential to relieve specific subtypes of chronic pain in adults, although controversies remain...
January 29, 2024: Biomedicines
#15
JOURNAL ARTICLE
Amy Jamieson, Marcel Grube, Samuel Leung, Derek Chiu, Amy Lum, Janice S Kwon, Aline Talhouk, Blake Gilks, Stefan Kommoss, Jessica N McAlpine
OBJECTIVES: Optimal management of patients with stage IA p53abn endometrial cancer without myoinvasion, classified as intermediate risk in the 2020 European Society of Gynaecological Oncology, European Society for Radiotherapy and Oncology, and European Society of Pathology (ESGO-ESTRO-ESP) guidelines, and the 2022 European Society of Medical Oncology (ESMO) guidelines, is currently unclear. Practice varies from surgery alone to adjuvant radiation±chemotherapy. Our aim was to assess the risk of disease recurrence in patients with stage IA p53abn endometrial cancer without myoinvasion compared with stage IA with myoinvasion (<50%)...
February 22, 2024: International Journal of Gynecological Cancer
#16
JOURNAL ARTICLE
Guillermo Suay, Francisco Aparisi, Oscar Juan-Vidal
No abstract text is available yet for this article.
February 20, 2024: Chinese Clinical Oncology
#17
JOURNAL ARTICLE
C Fan, Z Jiang, C Teng, X Song, L Li, W Shen, Q Jiang, D Huang, Y Lv, L Du, G Wang, Y Hu, S Man, Z Zhang, N Gao, F Wang, T Shi, T Xin
BACKGROUND: This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating patients with leptomeningeal metastases (LM) from non-small-cell lung cancer (NSCLC) who progressed from epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment in an expanded, prospective, single-arm, phase II clinical study (ChiCTR1800016615). PATIENTS AND METHODS: Patients with confirmed NSCLC-LM who progressed from TKI received IP (50 mg, day 1/day 5 for 1 week, then every 3 weeks for four cycles, and then once monthly) until disease progression or intolerance...
February 19, 2024: ESMO Open
#18
JOURNAL ARTICLE
J S W Borgers, A W van Schijndel, J V van Thienen, S Klobuch, T T P Seijkens, R P Tobin, L van Heerebeek, A Driessen-Waaijer, M W Rohaan, J B A G Haanen
BACKGROUND: Treatment with tumor-infiltrating lymphocytes (TILs) is rapidly evolving for patients with solid tumors. Following metastasectomy, TILs (autologous, intratumoral CD4+ and CD8+ T cells with the potential to recognize tumor-associated antigens) are isolated and non-specifically expanded ex vivo in the presence of interleukin-2 (IL-2). Subsequently, the TILs are adoptively transferred to the patients after a preconditioning non-myeloablative, lymphodepleting chemotherapy regimen, followed by administration of high-dose (HD) IL-2...
February 2024: ESMO Open
#19
REVIEW
Tasnim Khessib, Priyanka Jha, Guido A Davidzon, Andrei Iagaru, Jagruti Shah
Gynecologic malignancies, consisting of endometrial, cervical, ovarian, vulvar, and vaginal cancers, pose significant diagnostic and management challenges due to their complex anatomic location and potential for rapid progression. These tumors cause substantial morbidity and mortality, often because of their delayed diagnosis and treatment. An estimated 19% of newly diagnosed cancers among women are gynecologic in origin. In recent years, there has been growing evidence supporting the integration of nuclear medicine imaging modalities in the diagnostic work-up and management of gynecologic cancers...
February 10, 2024: Seminars in Nuclear Medicine
#20
REVIEW
Lorenzo Bernardi, Raffaello Roesel, Davit L Aghayan, Pietro E Majno-Hurst, Sara De Dosso, Alessandra Cristaudi
The use of preoperative or "neoadjuvant" chemotherapy (NAC) has long been controversial for resectable colorectal liver metastases (CRLM). The European Society of Medical Oncology (ESMO) 2023 guidelines on metastatic colorectal cancer (CRC) indicate a combination of surgical/technical and oncologic/prognostic criteria as the two determinants for allocating patients to NAC or upfront hepatectomy. However, surgical and technical criteria have evolved, and oncologic prognostic criteria date from the pre-modern chemotherapy era and lack prospective validation...
February 7, 2024: Cancer Treatment Reviews
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
